Cargando…

Quality of life in patients with neurofibromatosis type 1 and 2 in Canada

BACKGROUND: There is scarce data on the quality of life of people with neurofibromatosis type 1 (NF1) and type 2 (NF2) in Canada. METHODS: A cross-sectional study of adults with NF1 and NF2 attending a tertiary center. Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interferenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamoy-Jimenez, Geohana, Kim, Raymond, Suppiah, Suganth, Zadeh, Gelareh, Bril, Vera, Barnett, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317053/
https://www.ncbi.nlm.nih.gov/pubmed/32642740
http://dx.doi.org/10.1093/noajnl/vdaa003
_version_ 1783550544100458496
author Hamoy-Jimenez, Geohana
Kim, Raymond
Suppiah, Suganth
Zadeh, Gelareh
Bril, Vera
Barnett, Carolina
author_facet Hamoy-Jimenez, Geohana
Kim, Raymond
Suppiah, Suganth
Zadeh, Gelareh
Bril, Vera
Barnett, Carolina
author_sort Hamoy-Jimenez, Geohana
collection PubMed
description BACKGROUND: There is scarce data on the quality of life of people with neurofibromatosis type 1 (NF1) and type 2 (NF2) in Canada. METHODS: A cross-sectional study of adults with NF1 and NF2 attending a tertiary center. Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference) and disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2). We compared generic scores between NF1 and NF2 individuals and used regression models to assess factors associated with quality of life. RESULTS: Hundred and eighty-four participants were enrolled. Mean age was 33 years in NF1 and 40 years in NF2. NF1 and NF2 individuals had lower employment rates and lower scores in all domains of the SF-36 compared to the general Canadian population (P < .005). Using the EQ-5D-5L, there was a high proportion of pain (64% in NF1 and 74% in NF2) and anxiety/depression (60% in NF1 and 68% in NF2). Pain interference correlated with poor quality of life in NF1 and NF2; perceived physical appearance was the main predictor of mental well-being in NF1. CONCLUSIONS: Individuals with NF1 and NF2 have low quality of life, and this correlates with pain, anxiety, and depression, which are prevalent in NF1 and NF2. Perceived physical appearance predicts quality of life in NF1. A multidisciplinary approach is necessary for patients with NF1 and NF2, including mental health and pain management.
format Online
Article
Text
id pubmed-7317053
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-73170532020-07-07 Quality of life in patients with neurofibromatosis type 1 and 2 in Canada Hamoy-Jimenez, Geohana Kim, Raymond Suppiah, Suganth Zadeh, Gelareh Bril, Vera Barnett, Carolina Neurooncol Adv Supplement Articles BACKGROUND: There is scarce data on the quality of life of people with neurofibromatosis type 1 (NF1) and type 2 (NF2) in Canada. METHODS: A cross-sectional study of adults with NF1 and NF2 attending a tertiary center. Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference) and disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2). We compared generic scores between NF1 and NF2 individuals and used regression models to assess factors associated with quality of life. RESULTS: Hundred and eighty-four participants were enrolled. Mean age was 33 years in NF1 and 40 years in NF2. NF1 and NF2 individuals had lower employment rates and lower scores in all domains of the SF-36 compared to the general Canadian population (P < .005). Using the EQ-5D-5L, there was a high proportion of pain (64% in NF1 and 74% in NF2) and anxiety/depression (60% in NF1 and 68% in NF2). Pain interference correlated with poor quality of life in NF1 and NF2; perceived physical appearance was the main predictor of mental well-being in NF1. CONCLUSIONS: Individuals with NF1 and NF2 have low quality of life, and this correlates with pain, anxiety, and depression, which are prevalent in NF1 and NF2. Perceived physical appearance predicts quality of life in NF1. A multidisciplinary approach is necessary for patients with NF1 and NF2, including mental health and pain management. Oxford University Press 2020-01-10 /pmc/articles/PMC7317053/ /pubmed/32642740 http://dx.doi.org/10.1093/noajnl/vdaa003 Text en © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Articles
Hamoy-Jimenez, Geohana
Kim, Raymond
Suppiah, Suganth
Zadeh, Gelareh
Bril, Vera
Barnett, Carolina
Quality of life in patients with neurofibromatosis type 1 and 2 in Canada
title Quality of life in patients with neurofibromatosis type 1 and 2 in Canada
title_full Quality of life in patients with neurofibromatosis type 1 and 2 in Canada
title_fullStr Quality of life in patients with neurofibromatosis type 1 and 2 in Canada
title_full_unstemmed Quality of life in patients with neurofibromatosis type 1 and 2 in Canada
title_short Quality of life in patients with neurofibromatosis type 1 and 2 in Canada
title_sort quality of life in patients with neurofibromatosis type 1 and 2 in canada
topic Supplement Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317053/
https://www.ncbi.nlm.nih.gov/pubmed/32642740
http://dx.doi.org/10.1093/noajnl/vdaa003
work_keys_str_mv AT hamoyjimenezgeohana qualityoflifeinpatientswithneurofibromatosistype1and2incanada
AT kimraymond qualityoflifeinpatientswithneurofibromatosistype1and2incanada
AT suppiahsuganth qualityoflifeinpatientswithneurofibromatosistype1and2incanada
AT zadehgelareh qualityoflifeinpatientswithneurofibromatosistype1and2incanada
AT brilvera qualityoflifeinpatientswithneurofibromatosistype1and2incanada
AT barnettcarolina qualityoflifeinpatientswithneurofibromatosistype1and2incanada